Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz will be a leader in the development of innovative drug design strategies delivered via unique dermal product solutions to treat neurological and a variety of other disorders. The broad range of offerings includes solutions for pain modulation, appetite stimulation, smoking cessation, substitution treatment for opiate addiction, as well as alcohol abuse, and abuse deterrent formulations for opiates. AllTranz will utilize its unique dermal drug delivery technology to develop its own products for broad market appeal, as well as partner with pharmaceutical companies seeking to leverage the AllTranz technology platform to improve delivery of existing drugs to form new chemical entities thereby extending patent franchises.

Zynerba Pharmaceuticals (ZYNE) closed at $7.26 in the latest trading session, marking a -1.43% move from the prior day.

Zynerba Pharmaceuticals (ZYNE) Stock Moves -1.43%: What You Should Know

DEVON, Pa., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2019 Cantor Global Healthcare Conference. The presentation will take place on Thursday October 3rd at 8:55 AM EDT at the InterContinental New York Barclay. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.

Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Aurora Cannabis

Canopy Growth

Cronos Group

GW Pharmaceuticals

Tilray Brands

Cannabis (or marijuana) based medical products have the potential to become the next booming industry.

Epidolex Progresses: Will the Marijuana Drug Market Boom?

Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

Zynerba Releases Data on Epilepsy Candidate, Stock Down

Investors appear to be worried about potential safety issues with its cannabinoid gel.

Why Zynerba Pharmaceuticals Stock Is Crashing Today

Shares of cannabinoid drug maker Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) were set to to open sharply lower Wednesday morning.

Zynerba Plunges On Midstage Zygel Data In Epileptic Patients

- Study Achieves a 44% Median Seizure Reduction in Focal Impaired Awareness (Complex Partial) and Convulsive Seizures in DEE Patients by Month Two; Reductions were Sustained through Month Six of Treatment with Zygel -

Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)

Thinking about investing in medical cannabis? ZYNE stock is a lesser-known gem with transformative potential.

Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About

- Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS -

New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

- Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions –

Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

DEVON, Pa., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at two upcoming conferences in New York City.

Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

Aphria

Shopify

Constellation Brands

22nd Century Group

Despite another miserable month for marijuana stocks, these companies managed to buck the trend.

Only These 10 Pot Stocks Ended August Higher

DEVON, Pa., Aug.  29, 2019  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two posters at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium. The meeting is being held at Aston University in Birmingham, UK on September 4th through 6th, 2019. The posters will be viewable throughout September 5th and 6th and the authors will be available for additional discussion at the poster at the times noted below.

Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium

OrganiGram Holdings Inc.

We are on the brink of a massive market opportunity. For instance, a new report by Grand View Research reveals that the global legal marijuana market size is expected to reach $66.3 billion by the end of 2025.

5 Cannabis Stocks Set for Massive Gains

The stock cooled off along with its cannabis-based peers.

Here's Why Zynerba Pharmaceuticals Lost 21.8% in July

Zynerba Pharmaceuticals (ZYNE) reported in-line with market expectation in the second quarter with earnings meeting estimates.

Zynerba (ZYNE) Meets Earnings Estimates in Q2, Revenues Nil

The marijuana craze has hit this clinical-stage pharmaceutical company.

Here's Why Zynerba Pharmaceuticals Stock Soared 356% in the First Half of the Year

Adverum Biotechnologies

ArQule

Axsome Therapeutics

Provention Bio Inc

These biotech stocks have at least quadrupled in just over six months this year.

5 Best Biotech Stocks of 2019 So Far

Innovative Industrial Properties

Neptune Wellness Solutions Inc.

Village Farms International

Seven cannabis stocks doubled, and nearly two-thirds of all pot stocks ended the period higher.

The Best Marijuana Stocks in the First Half of 2019

Investors continue to show interest in the medical possibilities of cannabis-derived cannabidiol, or CBD, eagerly watching Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) as it begins patient trials on a CBD-infused skin gel aimed at treating Fragile X syndrome.

Canaccord Genuity Bullish On Zynerba Ahead Of CBD Gel Trial Data

Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.

Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

A new patent is generating excitement among investors for this clinical-stage biotech stock.

Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today

Zyernba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping. 
The post Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder appeared first on InvestorPlace.

Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for one of its cannabis-focused treatments.

Zynerba Advances Cannabidiol Treatment With New Patent Win

After tripling earlier in the year, few stocks have been as volatile in recent weeks than cannabinoid therapeutic concern Zynerba Pharmaceuticals.

News for Zynerba Pharmaceuticals Stock (ZYNE)